Bioequivalence Study Of Pediatric Appropriate Formulation
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
To determine bioequivalence of pediatric appropriate 80 mg atorvastatin formulation comparing
to the 80 mg commercial atorvastatin calcium tablet formulation.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.